The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma
- 1 April 1994
- journal article
- clinical trial
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 170 (4), 974-980
- https://doi.org/10.1016/s0002-9378(94)70090-7
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Cancer statistics, 1993CA: A Cancer Journal for Clinicians, 1993
- The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume Stage III epithelial ovarian cancer: A gynecologic oncology group studyGynecologic Oncology, 1992
- Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience.Journal of Clinical Oncology, 1991
- Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study.Journal of Clinical Oncology, 1989
- Therapy of stage III (optimal) epithelial carcinoma of the ovary with melphalan or melphalan plus corynebacterium parvum (a gynecologic oncology group study)Gynecologic Oncology, 1986
- A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer.Journal of Clinical Oncology, 1986
- A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A gynecologic oncology group studyCancer, 1986
- RANDOMISED TRIAL COMPARING TWO COMBINATION CHEMOTHERAPY REGIMENS (HEXA-CAF VS CHAP-5) IN ADVANCED OVARIAN CARCINOMAThe Lancet, 1984
- Advanced Ovarian AdenocarcinomaNew England Journal of Medicine, 1978